NASDAQ$CORT

Corcept Therapeutics Incorporated · Q2 2020 earnings

Q2 2020 earnings · · Investor relations

Briefing

Reported a 23 percent revenue increase and reaffirmed 2020 revenue guidance.

Corcept Therapeutics reported a revenue of $88.6 million for the second quarter of 2020, a 23% increase compared to the same period in 2019. The company's GAAP diluted net income per share was $0.23, and non-GAAP diluted net income per share was $0.32. They reaffirmed their 2020 revenue guidance of $355 – 375 million.

  • Revenue of $88.6 million, a 23 percent increase from second quarter 2019
  • GAAP diluted net income of $0.23 per share, compared to $0.17 per share in second quarter 2019
  • Non-GAAP diluted net income of $0.32 per share, compared to $0.25 per share in second quarter 2019
  • Cash and investments of $409.6 million, compared to $349.0 million at March 31, 2020

Headline financials

Total Revenue

$88.6M

Previous: $72.3M+22.6%
EPS (adj)

$0.32

Previous: $0.25+28.0%
Capital Expenditures

-$89K

Previous: -$667K+86.7%
Free Cash Flow

$28.2M

Previous: $19.5M+44.7%
Net Income

$28.3M

Previous: $20.2M+40.3%
Operating Income

$35.3M

Previous: $24.6M+43.1%
Gross Profit

$87.3M

Previous: $70.9M+23.2%
Cash & Equivalents

$410M

Previous: $58.1M+604.5%
Total Assets

$498M

Previous: $329M+51.5%
Stock-Based Comp

$8.49M

Previous: $7.74M+9.7%

Revenue & EPS history

Corcept Therapeutics · Revenue · Quarterly

$88.6M

Q2 2020+22.6%vs Q2 2019
Beat estimate in 6 of 16 quarters(38%)
ActualEstimate

Revenue by segment

Corcept Therapeutics · $103M total across 1 segment · Q2 2022

  • Product Revenue
    $103M

Forward guidance

Corcept Therapeutics reaffirms its 2020 revenue guidance of $355 - $375 million, expecting countervailing forces from the pandemic to continue in the coming quarters but remain manageable.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2020

Historical avgQ2 2020

+0.6%

Avg return

Earnings day

+1.7%

Avg return

5 days after

+7.0%

Avg return

30 days after

55%

35 / 64 earnings

Positive

+25.0%

Q2 2023

Best reaction

-18.5%

Q2 2013

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.2%+10.2%+49.1%
Q4 2025-1.8%-1.4%+3.1%
Q3 2025+7.7%+6.2%+21.1%
Q1 2025-4.4%-5.0%-6.7%
Q4 2024-5.6%-11.6%-13.8%
Q3 2024+1.6%+3.8%+19.6%
Q2 2024+1.5%-0.8%-3.3%
Q1 2024+7.5%+2.8%+29.4%
Q4 2023-6.2%-6.7%-4.0%
Q3 2023-9.9%-7.7%-7.5%
Q2 2023+25.0%+20.9%+32.4%
Q1 2023+7.2%+6.1%+3.9%
Q4 2022-5.2%-8.3%+3.3%
Q3 2022-11.4%-15.0%-13.4%
Q2 2022+1.2%+1.3%-8.5%
Q1 2022-13.6%-17.8%-3.9%
Q4 2021+17.5%+15.6%+25.9%
Q3 2021+11.5%+27.0%+16.0%
Q2 2021+1.8%+5.8%+5.5%
Q1 2021-2.6%-5.6%-1.2%
Q4 2020-0.5%-5.9%-11.2%
Q3 2020+4.4%+3.9%+34.2%
Q2 2020-6.4%-9.2%+24.3%
Q1 2020+8.5%+10.1%+18.9%
Q4 2019-1.8%-3.9%-25.9%
Q3 2019+5.3%+13.1%-6.7%
Q2 2019+11.0%+9.9%+12.0%
Q1 2019-9.7%-9.9%-15.7%
Q4 2018+5.3%+12.4%-1.1%
Q3 2018+7.1%+14.6%+18.6%
Q2 2018-5.8%-11.4%+5.1%
Q1 2018-4.2%-8.9%+2.3%
Q4 2017+4.5%+0.3%+5.9%
Q3 2017-9.3%-8.8%-4.7%
Q2 2017+7.3%+15.0%+33.7%
Q1 2017-4.9%-1.5%+18.6%
Q4 2016-5.3%+11.6%+8.5%
Q3 2016+8.2%+15.6%+14.6%
Q2 2016+1.7%+1.2%-7.3%
Q1 2016-5.9%
Q4 2015+4.3%
Q3 2015+8.1%
Q2 2015+8.2%
Q1 2015-4.8%
Q4 2014+4.9%
Q3 2014+0.6%
Q2 2014+5.0%
Q1 2014+0.5%
Q4 2013+1.4%
Q3 2013+1.7%
Q2 2013-18.5%
Q1 2013+4.3%
Q4 2012-1.0%
Q3 2012-18.1%
Q2 2012-4.7%
Q1 2012+9.2%
Q4 2011+2.8%
Q3 2011+3.9%
Q2 2011-4.0%
Q1 2011+2.9%
Q4 2010+0.0%
Q3 2010-1.4%
Q2 2009+3.3%
Q1 2010+0.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro